Skip to main content
Erschienen in: Der Hautarzt 5/2014

01.05.2014 | Leitthema

Dermatosen-imitierende kutane Arzneimittelreaktionen

verfasst von: Dr. N. Magnolo, T. Schwarz, S. Ständer

Erschienen in: Die Dermatologie | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Kutane unerwünschte Arzneimittelreaktionen (AMR) sind häufig und klinisch heterogen.

Methoden und Ergebnisse

AMR, die Dermatosen ähneln, werden zunehmend in Fallberichten beschrieben; genaue Daten zur Prävalenz liegen jedoch nicht vor. Häufig sind psoriasiforme, lichenoide und pityriasiforme Exantheme. Die Abgrenzung dieser Varianten von einer authentischen Dermatose ist schwierig und nur anhand einiger weniger klinischer und histologischer Kriterien möglich. Bei anderen Dermatosen wie dem Lupus erythematodes oder bullösen Dermatosen (Pemphigus vulgaris, bullöses Pemphigoid) sind arzneimittelinduzierte Varianten als Subentität der jeweiligen Krankheitsbilder bekannt.

Schlussfolgerung

Die genaue Erhebung der Anamnese und Bewertung des Verlaufs ist bei allen Dermatosen-ähnlichen AMR wesentlich und stellt den Kliniker vor eine echte Herausforderung. Eine sichere Differenzierung zwischen Dermatose und AMR ist jedoch nicht immer möglich.
Literatur
1.
Zurück zum Zitat Atzori L, Pinna AL, Ferreli C, Aste N (2006) Pityriasis rosea-like adverse reaction review of the literature and experience of an Italian drug-surveillance center. Dermatol Online J 12:1PubMed Atzori L, Pinna AL, Ferreli C, Aste N (2006) Pityriasis rosea-like adverse reaction review of the literature and experience of an Italian drug-surveillance center. Dermatol Online J 12:1PubMed
2.
Zurück zum Zitat Bastuji-Garin S, Joly P, Lemordant P et al (2011) Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol 131:637–643PubMedCrossRef Bastuji-Garin S, Joly P, Lemordant P et al (2011) Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol 131:637–643PubMedCrossRef
3.
Zurück zum Zitat Biazar C, Sigges J, Patsinakidis N et al (2013) Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev 12:444–454PubMedCrossRef Biazar C, Sigges J, Patsinakidis N et al (2013) Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev 12:444–454PubMedCrossRef
4.
Zurück zum Zitat Bircher AJ (2012) Uncomplicated drug-induced disseminated exanthemas. Chem Immunol Allergy 97:79–97PubMedCrossRef Bircher AJ (2012) Uncomplicated drug-induced disseminated exanthemas. Chem Immunol Allergy 97:79–97PubMedCrossRef
5.
Zurück zum Zitat Bremmer M, Deng A, Gaspari AA (2009) A mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease: Part 1. Dermatitis 20:182–192PubMed Bremmer M, Deng A, Gaspari AA (2009) A mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease: Part 1. Dermatitis 20:182–192PubMed
6.
Zurück zum Zitat Bremmer M, Deng A, Gaspari AA (2009) A mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease: Part 2. Dermatitis 20:243–256PubMed Bremmer M, Deng A, Gaspari AA (2009) A mechanism-based classification of dermatologic reactions to biologic agents used in the treatment of cutaneous disease: Part 2. Dermatitis 20:243–256PubMed
8.
Zurück zum Zitat Dalle Vedove C, Simon JC, Girolomoni G (2012) Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNFα agents. J Dtsch Dermatol Ges 10:889–897 Dalle Vedove C, Simon JC, Girolomoni G (2012) Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNFα agents. J Dtsch Dermatol Ges 10:889–897
10.
Zurück zum Zitat Goldberg I, Shirazi I, Brenner S (2008) In vitro interferon-gamma release test in patients with drug-induced pemphigus. Isr Med Assoc J 10:424–427PubMed Goldberg I, Shirazi I, Brenner S (2008) In vitro interferon-gamma release test in patients with drug-induced pemphigus. Isr Med Assoc J 10:424–427PubMed
11.
Zurück zum Zitat Kerl K (2012) Histopathological patterns indicative of distinct adverse drug reactions. Chem Immunol Allergy 97:61–78PubMedCrossRef Kerl K (2012) Histopathological patterns indicative of distinct adverse drug reactions. Chem Immunol Allergy 97:61–78PubMedCrossRef
12.
Zurück zum Zitat Kim GK, Del Rosso JQ (2010) Drug-provoked psoriasis: Is it drug induced or drug aggravated? Understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol 3:32–38PubMedPubMedCentral Kim GK, Del Rosso JQ (2010) Drug-provoked psoriasis: Is it drug induced or drug aggravated? Understanding pathophysiology and clinical relevance. J Clin Aesthet Dermatol 3:32–38PubMedPubMedCentral
13.
Zurück zum Zitat Kneisel A, Hertl M (2011) Autoimmune bullous skin diseases. Part 1: clinical manifestations. J Dtsch Dermatol Ges 9:844–856PubMed Kneisel A, Hertl M (2011) Autoimmune bullous skin diseases. Part 1: clinical manifestations. J Dtsch Dermatol Ges 9:844–856PubMed
14.
Zurück zum Zitat Kneisel A, Hertl M (2011) Autoimmune bullous skin diseases. Part 2: diagnosis and therapy. J Dtsch Dermatol Ges 9:927–947PubMed Kneisel A, Hertl M (2011) Autoimmune bullous skin diseases. Part 2: diagnosis and therapy. J Dtsch Dermatol Ges 9:927–947PubMed
15.
Zurück zum Zitat Kuwabara S, Maejima H, Watarai A et al (2012) A psoriasiform drug eruption induced by polyethylene glycol interferon-alpha-2b, successfully treated by narrow band ultraviolet B therapy. Eur J Dermatol 22:150–151PubMed Kuwabara S, Maejima H, Watarai A et al (2012) A psoriasiform drug eruption induced by polyethylene glycol interferon-alpha-2b, successfully treated by narrow band ultraviolet B therapy. Eur J Dermatol 22:150–151PubMed
16.
Zurück zum Zitat Lamchahab M, Qachouh M, Hali F et al (2012) Successive cutaneous adverse reactions to nilotinib and imatinib in a single patient. Ann Dermatol Venereol 139:828–831PubMedCrossRef Lamchahab M, Qachouh M, Hali F et al (2012) Successive cutaneous adverse reactions to nilotinib and imatinib in a single patient. Ann Dermatol Venereol 139:828–831PubMedCrossRef
17.
Zurück zum Zitat Lage D, Juliano PB, Metze K et al (2012) Lichen planus and lichenoid drug-induced eruption: a histological and immunohistochemical study. Int J Dermatol 51:1199–1205PubMedCrossRef Lage D, Juliano PB, Metze K et al (2012) Lichen planus and lichenoid drug-induced eruption: a histological and immunohistochemical study. Int J Dermatol 51:1199–1205PubMedCrossRef
18.
Zurück zum Zitat Lowe G, Henderson CL, Grau RH et al (2011) A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol 164:465–472PubMed Lowe G, Henderson CL, Grau RH et al (2011) A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol 164:465–472PubMed
19.
Zurück zum Zitat Maruani A, Machet MC, Carlotti A et al (2008) Immunostaining with antibodies to desmoglein provides the diagnosis of drug-induced pemphigus and allows prediction of outcome. Am J Clin Pathol 130:369–374PubMedCrossRef Maruani A, Machet MC, Carlotti A et al (2008) Immunostaining with antibodies to desmoglein provides the diagnosis of drug-induced pemphigus and allows prediction of outcome. Am J Clin Pathol 130:369–374PubMedCrossRef
20.
Zurück zum Zitat Nguyen K, Vleugels RA, Velez NF et al (2013) Psoriasiform reactions to anti-tumor necrosis factor alpha therapy. J Clin Rheumatol 19:377–381PubMedCrossRef Nguyen K, Vleugels RA, Velez NF et al (2013) Psoriasiform reactions to anti-tumor necrosis factor alpha therapy. J Clin Rheumatol 19:377–381PubMedCrossRef
21.
Zurück zum Zitat Papadavid E, Panayiotides I, Makris M et al (2013) Pityriasis rosea-like eruption associated with lamotrigine. J Am Acad Dermatol 68:e180–e181PubMedCrossRef Papadavid E, Panayiotides I, Makris M et al (2013) Pityriasis rosea-like eruption associated with lamotrigine. J Am Acad Dermatol 68:e180–e181PubMedCrossRef
22.
Zurück zum Zitat Pretel M, Marques L, Espana A (2014) Drug-induced lupus erythematosus. Actas Dermosifiliogr 105:18–30PubMedCrossRef Pretel M, Marques L, Espana A (2014) Drug-induced lupus erythematosus. Actas Dermosifiliogr 105:18–30PubMedCrossRef
23.
Zurück zum Zitat Ruocco V, Ruocco E, Lo Schiavo A et al (2013) Pemphigus: etiology, pathogenesis, and inducing or triggering factors: facts and controversies. Clin Dermatol 31:374–381PubMedCrossRef Ruocco V, Ruocco E, Lo Schiavo A et al (2013) Pemphigus: etiology, pathogenesis, and inducing or triggering factors: facts and controversies. Clin Dermatol 31:374–381PubMedCrossRef
24.
Zurück zum Zitat Seneschal J, Milpied B, Taieb A (2012) Cutaneous drug eruptions associated with the use of biologies and cutaneous drug eruptions mimicking specific skin diseases. Chem Immunol Allergy 97:203–216PubMedCrossRef Seneschal J, Milpied B, Taieb A (2012) Cutaneous drug eruptions associated with the use of biologies and cutaneous drug eruptions mimicking specific skin diseases. Chem Immunol Allergy 97:203–216PubMedCrossRef
25.
Zurück zum Zitat Stavropoulos PG, Soura E, Antoniou C (2014) Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol, doi: 10.1111/jdv.12366 [Epub ahead of print] Stavropoulos PG, Soura E, Antoniou C (2014) Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol, doi: 10.1111/jdv.12366 [Epub ahead of print]
26.
Zurück zum Zitat Turk BG, Gunaydin A, Ertam I, Ozturk G (2013) Adverse cutaneous drug reactions among hospitalized patients: five year surveillance. Cutan Ocul Toxicol 32:41–45PubMedCrossRef Turk BG, Gunaydin A, Ertam I, Ozturk G (2013) Adverse cutaneous drug reactions among hospitalized patients: five year surveillance. Cutan Ocul Toxicol 32:41–45PubMedCrossRef
27.
Zurück zum Zitat Wendling D, Biver-Dalle C, Vidon C et al (2013) Lichen planus under anti TNF therapy for ankylosing spondylitis. Joint Bone Spine 80:227–228PubMedCrossRef Wendling D, Biver-Dalle C, Vidon C et al (2013) Lichen planus under anti TNF therapy for ankylosing spondylitis. Joint Bone Spine 80:227–228PubMedCrossRef
28.
Zurück zum Zitat Williams VL, Cohen PR (2011) TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol 50:619–625PubMedCrossRef Williams VL, Cohen PR (2011) TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol 50:619–625PubMedCrossRef
29.
Zurück zum Zitat Yamamoto M, Ikeda M, Kodama H, Sano S (2008) Transition of psoriasiform drug eruption to psoriasis de novo evidenced by histopathology. J Dermatol 35:732–736PubMedCrossRef Yamamoto M, Ikeda M, Kodama H, Sano S (2008) Transition of psoriasiform drug eruption to psoriasis de novo evidenced by histopathology. J Dermatol 35:732–736PubMedCrossRef
Metadaten
Titel
Dermatosen-imitierende kutane Arzneimittelreaktionen
verfasst von
Dr. N. Magnolo
T. Schwarz
S. Ständer
Publikationsdatum
01.05.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Dermatologie / Ausgabe 5/2014
Print ISSN: 2731-7005
Elektronische ISSN: 2731-7013
DOI
https://doi.org/10.1007/s00105-013-2697-8

Weitere Artikel der Ausgabe 5/2014

Der Hautarzt 5/2014 Zur Ausgabe

Panorama Dermatologische Praxis

Panorama Dermatologische Praxis

Kurzkasuistiken

Lichen ruber mucosae

Einführung zum Thema

Kutane Arzneimittelreaktionen

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.